Investors & Media

Corporate Profile

DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, we are dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV Technologies is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY.

Investor Relations


Sara Blum Sherman
Senior Director
Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

Media Relations


Joe Becker
VP, Global Corporate Communications
+1 646-650-3912
joseph.becker@dbv-technologies.com

Subscribe
to get the latest
DBV press releases

Press Releases

DocumentYearTerms

06/04/2020 - 10:30 pm

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

Download PDF (241 KB)

06/02/2020 - 10:30 pm

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Download PDF (169 KB)

05/12/2020 - 10:01 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020

Download PDF (160 KB)